Head of the department- hematologist- Maya V. Solovieva, Candidate of Medical Sciences, hematologist of the highest qualification category

The department functions as part of the Division of Chemotherapy of Paraproteinemic Hemoblastosis.

The department, as an independent clinical unit, was organized in 2022. The need to open this department as part of the Division of Chemotherapy of Paraproteinemic Hemoblastosis was dictated by the increased need for diagnostic and therapeutic measures for patients with various plasma cell tumors in outpatient settings. Doctors working in the day hospital participate in rounds and are on duty in the round-the-clock Department of Hematology and Chemotherapy of Paraproteinemic Hemoblastosis with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit, which provides in-depth knowledge of the course of the disease in patients with plasma cell tumors receiving intensive antitumor treatment. Close cooperation with the department's round-the-clock hospitals makes it possible to maintain continuity in patient therapy.

List of diseases and syndromes with which patients can be referred for examination, differential diagnosis and treatment:

The head of the department is hematologist, Doctor of Medical Sciences, Irina G. Rekhtina .

The department functions as part of the Division of Chemotherapy of Paraproteinemic Hemoblastoses.

The department was opened in 2019 with the goal of developing a scientifically based approach to the diagnosis, treatment and monitoring of plasma cell tumors, including AL amyloidosis, multiple myeloma, POEMS syndrome, immunoglobulin deposit disease and other monoclonal gammopathies of clinical significance.

The priority of the department is the diagnosis and treatment of rare and insufficiently studied diseases of clonal plasma nature.

The head of the department is hematologist — Larisa A. Kuzmina, Candidate of Medical Sciences.

The Hematology Clinic of the Institute of Blood Transfusion was established in 1927 on the initiative of professors M.P. Konchalovsky and H.H. Vlados.

From 1969-1988 the head of the Hematology Clinic was the Honored Worker of Science of the RSFSR, a participant in the Second World War, Professor F.E. Feinstein. Under his leadership, work continued on the study of leukemia, lymphomas, aplastic anemia, and hemolytic anemia; treatment protocols were improved for these diseases; programs were developed for the treatment of leukemia, aplastic anemia, including bone marrow transplantation. F.E. Feinshtein is one of the authors of the monographs “Diseases of the Blood System” (1980, 1987), “Hematopoietic Depression” (1987).

In 1972, the first 8-bed transplant unit was opened in the clinic, where under the guidance of L.S. Lyubimova, from 1972-74, the first studies were conducted on the treatment of patients with aplastic anemia with intravenous administration of allogeneic bone marrow using anti- lymphocytic globulin. In 1977 L.S. Lyubimova and L.P. Mendeleeva performed the first transplantation of allogeneic bone marrow in a patient with acute lymphoblastic leukemia with conditioning with high doses of cyclophosphane.

Head of the department- hematologist — Zalina T. Fidarova, Candidate of Medical Sciences

The main focus of the department is the study of the biological phenomena underlying leukemia, myelodysplastic syndromes, aplastic anemia, and a scientifically based approach to the treatment of these diseases, the creation of new treatment programs, and their introduction into wide hematological practice.

The Department of Hemoblastosis and Hematopoietic Depression Chemotherapy with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit was originally called the Hematology Clinic of the Institute of Blood Transfusion (Hematological Research Center of the Ministry of Health of the Russian Federation), established in 1927 on the initiative of professors M.P. Konchalovsky and H.H. Vlados.

The first head of the department, from 1927 to 1953, was Corresponding Member of the USSR Academy of Medical Sciences, Professor H.H. Vlados.

The head of the department is hematologist, Irina A. Lukyanova, Candidate of Medical Sciences.

The department was formed in October 2018. From 2018 to 2021, the department was headed by Candidate of Medical Sciences, Zalina T. Fidarova, from 2022 — Candidate of Medical Sciences, doctor of the first category, Irina A. Lukyanova.

The department, together with the Department of Hemoblastosis and Hematopoietic Depression Chemotherapy with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit, is developing a scientifically based approach to the treatment of leukemia, myelodysplastic syndromes, aplastic anemia, as well as creating new treatment programs and introducing them into wide-ranging hematology practice. All stages of hemoblastosis therapy are performed in the department: from induction to maintenance treatment; replacement hemotransfusion therapy; immunosuppressive therapy of patients with aplastic anemia; dispensary observation of patients who have completed program therapy.

The staff of the department are highly qualified experts in the field of leukemia and hematopoietic depressions. They participate in all conferences "Leukemias and lymphomas. Therapy and Fundamental Research" conducted by the NMRC for Hematology, send abstracts and take part in annual international and domestic conferences on hematology. They are organizers, experts and participants of Russian congresses on hematology and present the results of their scientific and clinical developments at many regional conferences across Russia.

The head of the department is hematologist, Vera A. Vasilieva, Candidate of Medical Sciences.

The department as an independent unit was opened in November 2018 However, since 2016, the doctors of this unit have been engaged in outpatient admission of patients after BMT within the Department of Intensive High-Dose Chemotherapy and Bone Marrow Transplantation with Round-the-Clock Hospital (Head of the Department – Cand. Sci. (Med.), L.A. Kuzmina.)

The department is indispensable due to the increasing number of patients after BMT. The experience accumulated by the department in managing patients helps to coherently monitor, carry out diagnostic and preventive procedures for patients after BMT, and prevent serious complications at early stages. Patients are monitored throughout their entire subsequent life after allo-HSCT, more thoroughly during the first year after allogeneic BMT, since all significant events occur at this time. Particular attention is paid to patients with chronic GVHD, prevention of relapses and the presence of other complications after allo-HSCT.

In order to improve the quality of medical care, the doctors of the department created the "Patient Schools" project, which highlights potential problems and all topical issues related to allo- HSCT. All school lessons are recorded as video recommendations and posted on the website for transplant patients ( tkm.blood.ru ).